| Margins | Focus on high-value low-volume niche products for margin insulation. |
|---|---|
| Demand visibility | Strong demand for niche, anti-diabetic, and cardiology products. |
| Management confidence | High; citing 'strategic readiness' and 'future growth'. |
Growth
External API sales reported at ~95.1 Cr INR for FY26. Post-acquisition, Raghava Life Sciences plant has 200 Cr INR revenue potential.
Outlook
Acquiring Actis Generics (~80 Cr) and Raghava Life Sciences (~135 Cr). Partnered with InvAscent for 40% equity (243.33 Cr).
Risks
Reliance on captive sales to parent RPGLS; integration risks of two simultaneous acquisitions (Actis Generics and Raghava Life Sciences).
Investor Presentation filed with BSE, NSE: RPGLIFE. Summary written with AI assistance from the document.
RPG Life Sciences Ltd: key numbers
- Share price
- ₹3,050.60
- Market cap
- ₹5,045 Cr
- Revenue (annual)
- ₹707.5 Cr
- Net profit (annual)
- ₹115.2 Cr
- P/E (TTM)
- 42.2×Sector 50.4×
- Promoter holding
- 72.95%+0.00% QoQ
- FII holding
- 0.95%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from RPG Life Sciences Ltd
All →RPG Life Sciences Merger & Restructuring
RPG Life Sciences announced the amalgamation of its wholly-owned subsidiary, Actis Generics, into its other subsidiary, RPG Active Pharma Limited. No share exchange is involved.
RPG Life Sciences Acquisition
RPG Life Sciences completed its acquisition of the entire stake in Actis Generics Private Limited, making it a subsidiary of the company.
RPG Life Sciences Price Movement Clarification
RPG Life Sciences clarified that the recent increase in its trading volume is attributable to market conditions and there is no undisclosed price-sensitive information.
RPG Life Sciences Merger & Restructuring
RPG Life Sciences completed the slump sale of its API and intermediates business to Raghava Life Sciences Private Limited, effective September 16, 2026.
RPG Life Sciences Merger & Restructuring Worth ₹243.3 Cr
RPG Life Sciences' subsidiary, RPG Active Pharma, allotted shares to India Life Sciences Fund and Vistaject Fund for ₹243.33 crores. Post-allotment, RPG Active Pharma remains a subsidiary.
- Value
- ₹243.3 Cr
RPG Life Sciences Acquisition Worth ₹135 Cr
RPG Life Sciences' subsidiary, RPG Active Pharma, will acquire the API business of Raghava Life Sciences for up to ₹135 Crore, expanding its manufacturing capabilities.
- Value
- ₹135.0 Cr
- manufacturing capacity
- 300.0 KL